Mastiplan LC is used as part of the management strategy for clinical mastitis in lactating dairy cows, applying supportive relief to both the infectious agent and the resulting acute symptomatic distress.

---

The antibiotic component is relevant for addressing the presence of susceptible bacterial pathogens. The product supports the reduction of associated symptoms related to inflammatory or irritative states.

“This supportive relief contributes to easing the overall symptom load during periods of heightened symptoms.”

Relief for Acute Inflammation and Infection

Mastiplan LC is applied across domains where additional symptomatic support is needed in conditions associated with acute or disruptive episodes. The medication is relevant for easing symptom clusters that include pronounced swelling, heat, and painful firmness of the affected quarter. The therapy contributes to easing the overall symptom load and assists with maintaining functional stability of the affected quarter.

Therapeutic Focus
The product is commonly used when symptoms related to physical discomfort and inflammatory states become more noticeable during lactation.

Regulatory References

1. UK Veterinary Medicines Directorate (VMD) Summary of Product Characteristics

Eligibility Map: Who can and cannot use Mastiplan LC — official regulatory information

The eligibility profile for Mastiplan LC is defined by the official regulatory documents, which govern the approved species, conditions of use, and populations for which the product is contraindicated.

Eligibility Scope

Classification	Population/Condition	Restriction Detail
Intended Use	Cattle (lactating cows)	For clinical mastitis caused by pathogens sensitive to Cefapirin.
Contraindicated	Animals with Hypersensitivity	Do not use if allergic to cephalosporins, other beta-lactam antibiotics, or any excipients.
Conditional Use	Pregnant/Breeding Animals	Use only according to a benefit/risk assessment by the responsible veterinarian.

Eligibility-Related Restrictions

Use of Mastiplan LC must adhere to official, national, and regional antimicrobial policies. Eligibility for treatment requires that the target pathogens be identified, and their susceptibility to Cefapirin be confirmed, as stated in regulatory guidelines. The feeding of waste milk containing antibiotic residues to calves must be avoided to mitigate the risk of developing antimicrobial resistance.

Connection to the overall eligibility profile

The official documents strictly define who can and cannot use the medicine by limiting use to lactating cows under specific diagnostic criteria and microbial susceptibility. Exclusion is mandatory for cows with a known hypersensitivity to the antibiotic components. Eligibility for use in pregnant animals is conditional, relying on a professional risk assessment rather than blanket approval.

Interactions with other medicines and products

This section describes the officially documented interaction patterns for Mastiplan LC (Cefapirin and Prednisolone Acetate) strictly as stated in government regulatory sources, without including therapeutic claims, dosage instructions, or general safety advice.

Documented Pharmacodynamic and Restriction Patterns

The regulatory profile identifies specific restrictions and risks associated with co-administration of certain medicinal products. Officially documented interactions fall into two primary categories:

1. Pharmacodynamic Antagonism: Concurrent use with bacteriostatic antibiotics may cause antagonistic effects. This is a functional interaction where the efficacy of the bactericidal component, Cefapirin, is diminished by agents that rely on different mechanisms of action.
2. Additive Organ Toxicity Risk: Regulatory documents state that the concurrent use of parenteral aminoglycosides or other nephrotoxic drugs is not recommended. This restriction is based on the potential for an additive risk of adverse effects, such as organ toxicity.

Absence of Documented Pharmacokinetic Interactions

The official product labels do not contain specific information regarding pharmacokinetic interactions mediated by common metabolic enzymes (e.g., CYP) or drug transporters (e.g., P-gp). No mandatory timing-based separation rules or explicit contraindicated combinations are documented in the interaction section of the regulatory labeling. All stated interactions are regulatory cautions regarding potential incompatibility or additive risk.

Mastiplan LC is a combination product featuring two distinct pharmacological mechanisms within the targeted tissue. The first active substance, Cefapirin, is a first-generation cephalosporin. Cefapirin operates as a beta-lactam antibiotic, targeting the bacterial cell wall synthesis pathway. It specifically inhibits the transpeptidases (Penicillin-Binding Proteins or PBPs) responsible for cross-linking the peptidoglycan layer, which is crucial for structural integrity. This inhibition disrupts the assembly of the bacterial wall, leading to a mechanistic cascade that results in the loss of osmotic stability and subsequent bactericidal activity. This mechanism is time-dependent.

The second substance, Prednisolone, is a glucocorticoid, a corticosteroid hormone analogue. Prednisolone exerts its effect by binding to intracellular glucocorticoid receptors (GRs). The activated GR complex translocates to the nucleus and modulates gene expression. This modulation primarily involves the transcription of anti-inflammatory proteins (transactivation) and the suppression of pro-inflammatory gene transcription (transrepression). Specifically, it inhibits the release of arachidonic acid metabolites and suppresses the activity of key inflammatory mediators, thereby intervening in both the early and late phases of the local inflammatory cascade.

How to Use Mastiplan LC

The administration of Mastiplan LC follows a specific protocol that outlines the required route, dose, and frequency.

---

Administration and Dosage Regimen

The medicine is designed strictly for intramammary use, meaning it is administered directly into the udder quarter via the teat canal. The standard dose involves the full contents of one single-use syringe being infused into each affected quarter. This unit dose contains the prescribed amount of Cefapirin and Prednisolone Acetate.

Frequency and Course Duration

Treatment is structured as a course over consecutive milkings, with the specific frequency depending on the milking routine:

Milking Frequency	Administration Interval	Course Duration
Twice Daily	Every 12 hours	Four consecutive milkings
Once Daily	Every 24 hours	Three consecutive milkings

---

Procedural Context for Administration

Administration must occur immediately after the affected udder quarter has been completely milked out, establishing a critical time-relationship to ensure proper local distribution. Before infusion, the teat and its orifice must be thoroughly cleaned and disinfected using the provided cleaning towel. After the full contents of the single-use syringe have been infused, the product is dispersed by gentle massage of the teat and the udder. The product is intended for use in dairy cows during the lactation period.

Research Evidence / Overview of Studies for Mastiplan LC

---

Evidence for Management of Clinical Mastitis

The research supporting Mastiplan LC was evaluated in the context of clinical mastitis in lactating dairy cows. This evidence base primarily consists of regulatory clinical trials used to support official product authorization, alongside controlled experimental challenge studies published in scientific literature. These studies applied in research contexts involving fluctuating or unstable symptoms that occur during an acute mastitis episode.

Study Focus on Bacteriological and Clinical Outcomes

The main focus of the research was on dual outcomes: bacteriological status and clinical signs. Studies monitored the bacteriological outcomes by tracking the patterns of pathogen presence or absence in the quarter. Furthermore, studies explored clinical outcomes which included measures of inflammatory or irritative states. This involved measuring the patterns of change for visible signs of disease. Reports described patterns observed in the studies regarding the timeframe for the affected quarter to return to its normal size and temperature.

Evidence in Study Populations and Functional Measures

The populations evaluated in the research were specific. The results apply only to the populations studied, which were lactating dairy cows with mastitis caused by organisms sensitive to Cefapirin. Researchers also examined the medicine's influence on functional measures used to assess udder health. This included monitoring functional measures, specifically by tracking patterns in the Somatic Cell Count (SCC) in the milk.

---

What Remains Unclear or Requires Further Research

This section synthesizes the areas where data is limited or where further research is needed. This evidence highlights what is known — and what is still uncertain.

• Long-Term Outcomes: Long-term effects are not fully established because trial follow-up durations were limited to the short and intermediate terms necessary for regulatory review. There is limited information for long-term outcomes regarding milk quality extending significantly beyond four weeks post-treatment.
• Study Context and Severity: The research landscape shows that some outcomes and comparison data were observed in some studies using controlled experimental challenge models. These models may differ from the complexity and full spectrum of naturally occurring mastitis cases. Specifically, data for certain groups remain insufficient, and there is limited information available concerning the medicine's evaluation in severe, naturally occurring cases of the condition.

Key Studies & References

1. Mastiplan LC, 300mg/20mg (Cefapirin/Prednisolone), intramammary suspension for lactating cows - Summary of Product Characteristics (SPC)
2. Mastiplan LC, 300mg/20mg (Cefapirin/Prednisolone), intramammary suspension for lactating - HPRA

Common questions about Mastiplan LC (FAQ)

---

Q: How quickly does Mastiplan LC start working?

Official product information indicates that Mastiplan LC is formulated with a corticosteroid component intended to promote a reduction in local swelling and quarter temperature soon after the intramammary application. The active substances are present in the milk over the course of the treatment intervals (12 or 24 hour intervals), reflecting the medication's designed action at the site of infection.

Q: How long does the effect of Mastiplan LC last?

The duration of the product's presence is indicated by the official milk and meat withdrawal periods. Regulatory documents specify that the minimum milk withdrawal period is 5.5 days (132 hours) after the last administration, which specifies the time required for residues to fall below acceptable safety limits.

Q: Is it normal to see a small local reaction after using Mastiplan LC?

The official safety profile only lists systemic hypersensitivity (allergic reaction) as the single adverse reaction, categorized as a very rare event (less than 1 in 10,000 animals). Official documents do not specify the frequency of minor, localized reactions or irritations that may occur.

Q: Are there any long-term effects of using Mastiplan LC?

Studies conducted in lab animals showed no evidence of reproductive toxicity, birth defects, or maternal toxicity. Official guidelines state that use in breeding animals is conditional, requiring a benefit/risk assessment by the responsible veterinarian.

Q: Can Mastiplan LC be given along with anti-inflammatory drugs?

The product contains the anti-inflammatory corticosteroid Prednisolone. Regulatory documents advise against concurrent use with specific categories of drugs, such as bacteriostatic antibiotics (due to potential functional conflict) and parenteral aminoglycosides or other nephrotoxic drugs (due to the risk of organ toxicity).

Q: What are the withdrawal times associated with Mastiplan LC?

The official withdrawal periods are set out in the regulatory information. The withdrawal period for meat and offal is 4 days (96 hours), and the withdrawal period for milk is 5.5 days (132 hours) after the last administration.

Q: Does Mastiplan LC affect the quality of milk after treatment?

Mastiplan LC is intended to treat bacterial clinical mastitis, an infection that negatively affects milk quality. The corticosteroid component is described as promoting a reduction in swelling and inflammation, which supports the return of the quarter to its normal state.

Q: Why is proper administration of Mastiplan LC so important?

Official regulatory warnings indicate that any use deviating from the prescribed instructions, including technique and dose, may reduce the effectiveness of the treatment. Incorrect use can also increase the selection and spread of antimicrobial-resistant bacteria.

Q: Can Mastiplan LC be used for subclinical mastitis?

No. The official indications for Mastiplan LC specify that it is intended only for the treatment of clinical mastitis in lactating dairy cows caused by pathogens sensitive to its antibiotic component.

Q: Does using Mastiplan LC contribute to antibiotic resistance?

Official use guidelines require compliance with national and regional antimicrobial policies. To help mitigate the risk of resistance, feeding waste milk containing residues of Cefapirin to calves must be avoided.

Q: Does Mastiplan LC have different dosing for different animal sizes?

Official administration guidelines state that the dose is standardized. The full contents of one syringe are infused into each affected quarter, regardless of the animal's weight or size.

Q: What happens if Mastiplan LC is administered incorrectly?

Official warnings state that incorrect use, including deviations from the specified administration procedure, can reduce the effectiveness of the treatment. This also increases the prevalence of bacterial resistance to the antibiotic component.

Q: Can Mastiplan LC be used for prevention, or only treatment?

Official product indications specify that Mastiplan LC is approved for the treatment of clinical mastitis. It is not approved or indicated for preventive use.

Q: Is Mastiplan LC safe for the environment?

Official guidelines require that all unused product or waste material be disposed of according to local environmental requirements. This is critical because the product should not be disposed of via wastewater or household waste.

Q: Can I buy Mastiplan LC without a vet visit?

Mastiplan LC is classified as a prescription-only veterinary medicine. As such, its use requires the authorization of a veterinarian.

Q: Does Mastiplan LC contain penicillin?

The antibiotic component of Mastiplan LC is Cefapirin, which belongs to the cephalosporin class, not the penicillin class. However, the product is contraindicated in animals with known hypersensitivity to either cephalosporins or other beta-lactam antibiotics.

Q: Is Mastiplan LC used for chronic mastitis cases?

The official product indications specify that Mastiplan LC is approved for the treatment of clinical mastitis caused by sensitive pathogens. It is not specifically indicated for chronic mastitis.

Q: Why is Mastiplan LC administered directly into the udder?

The administration route is strictly intramammary to ensure the active substances are delivered directly to the site of infection. This local application is designed to achieve the necessary high concentrations for therapeutic effect.

Q: Are there specific age restrictions for the animal being treated with Mastiplan LC?

The target species listed in regulatory documents is cattle, and the product is specifically intended for use only in lactating cows.

Q: What happens if a partial dose of Mastiplan LC is given?

The standard dose is defined as the full contents of a single syringe. Official guidance warns that administering less than the full, prescribed dose may reduce the overall effectiveness of the treatment and contribute to the risk of antibiotic resistance.

Q: Are there different formulations of Mastiplan LC?

Official documentation describes the product as a single, consistent formulation—an oily intramammary suspension. There are no other approved formulations available.

Q: What is the shelf life of Mastiplan LC?

The official shelf life for Mastiplan LC as packaged for sale is typically three years, provided the storage instructions (such as storing below 25 C and protecting from light) are strictly followed.

Q: Can Mastiplan LC treat viral infections?

No. The active component is an antibacterial agent effective against specific types of bacteria. It is not indicated or effective for treating viral infections.

Q: Why do some mastitis cases not respond to Mastiplan LC?

Official guidelines indicate that the product is only effective against mastitis caused by pathogens that are proven to be sensitive to Cefapirin. Lack of response may be due to an organism that is not susceptible to the antibiotic component.

Q: How is the safety of Mastiplan LC monitored after it's released?

Regulatory documents state that continuous safety monitoring is maintained through a pharmacovigilance system. This relies on the reporting of adverse events by users and veterinarians to the marketing authorization holder or the national competent authority.

Q: Does Mastiplan LC have any special disposal instructions?

Official disposal guidelines state that due to potential environmental risk, the product should not be discarded into water systems. Disposal of the unused product or waste material must follow specific local regulations.

How to Store and Dispose of Mastiplan LC?

Official regulatory documents define specific requirements for the storage, handling, and disposal of Mastiplan LC (intramammary suspension).

Storage Requirements

Constraint	Requirement
Temperature	Store below 25 C.
Protection	Keep the syringes in the inner aluminium sachet and the outer carton.
Child Safety	Keep out of the sight and reach of children.

Disposal Requirements

Constraint	Requirement
Environmental	Do not dispose of the product via wastewater or household waste.
Waste Handling	Unused veterinary medicinal product and waste materials must be disposed of in accordance with local requirements.